Get the Stockscreener App
8.07
2.67%
0.21
After Hours:
8.07
Elicio Therapeutics Inc stock is traded at $8.07, with a volume of 47,114.
It is up +2.67% in the last 24 hours and up +0.88% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$7.86
Open:
$7.87
24h Volume:
47,114
Relative Volume:
0.47
Market Cap:
$139.28M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.3154
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
+2.02%
1M Performance:
+0.88%
6M Performance:
+2.02%
1Y Performance:
+39.14%
1-Day Range:
$7.83
$8.10
1-Week Range:
$7.77
$8.305
52-Week Range:
$4.60
$12.62
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
8.07 | 135.65M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
How (ELTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
What is the fair value of Elicio Therapeutics Inc. stock nowJuly 2025 Drop Watch & Technical Entry and Exit Alerts - Улправда
Dividend Watch: Can Elicio Therapeutics Inc. stock hit record highs again2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - Улправда
Aug Decliners: Why Elicio Therapeutics Inc stock could rally in 2025July 2025 Setups & Verified Chart Pattern Signals - moha.gov.vn
How Elicio Therapeutics Inc. stock reacts to Fed rate cutsCPI Data & Fast Entry High Yield Stock Tips - ulpravda.ru
Will Elicio Therapeutics Inc. stock benefit from green energy trendsWeekly Investment Summary & Reliable Entry Point Alerts - Улправда
Is Elicio Therapeutics Inc. stock ready for breakoutJuly 2025 Gainers & Entry Point Confirmation Alerts - Bölüm Sonu Canavarı
How rising interest rates impact Elicio Therapeutics Inc. stockJuly 2025 Price Swings & Fast Momentum Stock Entry Tips - Улправда
FOMO Trade: Can Elicio Therapeutics Inc. stock hit record highs again2025 Geopolitical Influence & Entry and Exit Point Strategies - Улправда
How supply chain issues affect Elicio Therapeutics Inc. stockMarket Movers & Reliable Breakout Forecasts - DonanımHaber
Why Elicio Therapeutics Inc. stock could rally in 2025Earnings Risk Summary & Weekly High Potential Alerts - Улправда
Can Elicio Therapeutics Inc. stock withstand economic slowdownLong Setup & AI Forecasted Entry and Exit Points - Улправда
Elicio Therapeutics Earnings Notes - Trefis
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - The Manila Times
Elicio Therapeutics (Nasdaq: ELTX) issues 157K options at $8.52 - Stock Titan
Understanding Momentum Shifts in (ELTX) - Stock Traders Daily
Elicio Therapeutics (ELTX) upgraded to buy: Here's why - MSN
Elicio’s cancer vaccine triggers broad anti-tumor immunity - Rare Cancer News
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Regeneron (REGN) and Elicio Therapeutics (ELTX) - The Globe and Mail
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why - sharewise.com
Elicio reports antigen spreading in 87% of evaluated cancer patients - Investing.com
Elicio reports antigen spreading in 87% of evaluated cancer patients By Investing.com - Investing.com Australia
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial - Yahoo Finance
Pancreatic Ductal Adenocarcinoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Elicio Therapeutics, Cend Therapeutics, Silenseed, Amplia - Barchart.com
How Elicio Therapeutics Inc. (9HA) stock reacts to stronger dollarQuarterly Market Summary & Safe Capital Allocation Plans - Newser
How Elicio Therapeutics Inc. (9HA) stock reacts to new regulations2025 Winners & Losers & Long-Term Growth Plans - Newser
Will Elicio Therapeutics Inc. (9HA) stock benefit from mergersTrade Ideas & Risk Controlled Swing Trade Alerts - Newser
Avoiding Lag: Real-Time Signals in (ELTX) Movement - Stock Traders Daily
Can Elicio Therapeutics Inc. stock deliver surprise earnings beat2025 Volatility Report & Real-Time Buy Zone Alerts - Newser
Can Elicio Therapeutics Inc. (9HA) stock sustain margin levelsAnalyst Downgrade & Safe Capital Growth Plans - Newser
Will Elicio Therapeutics Inc. stock benefit from AI adoptionWeekly Stock Recap & Weekly Stock Performance Updates - Newser
How Elicio Therapeutics Inc. (9HA) stock trades in high volatilityWeekly Trade Recap & Weekly Return Optimization Alerts - Newser
Is Elicio Therapeutics Inc. (9HA) stock undervalued historicallyTreasury Yields & Technical Analysis for Trade Confirmation - Newser
Will Elicio Therapeutics Inc. (9HA) stock split increase liquidity2025 Earnings Surprises & Fast Moving Market Watchlists - Newser
How Elicio Therapeutics Inc. (9HA) stock compares with top peers - Newser
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025 - MSN
Discipline and Rules-Based Execution in ELTX Response - news.stocktradersdaily.com
Can Elicio Therapeutics Inc. (9HA) stock sustain breakout momentumQuarterly Market Summary & High Accuracy Swing Entry Alerts - newser.com
Is Elicio Therapeutics Inc. stock a smart buy before Fed meeting2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Why Elicio Therapeutics Inc. (9HA) stock remains stableProfit Target & Consistent Return Investment Signals - newser.com
How Elicio Therapeutics Inc. stock performs in weak economyJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
Can Elicio Therapeutics Inc. stock maintain operating marginsQuarterly Growth Report & Stock Timing and Entry Methods - newser.com
Retail investors are Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) biggest owners and were hit after market cap dropped US$8.5m - simplywall.st
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):